Trump has begun another trade war. Here's a timeline of how we got here
Canada's leader laments lost friendship with US in town that sheltered stranded Americans after 9/11
Chinese EV giant BYD's fourth-quarter profit leaps 73%
You're an American in another land? Prepare to talk about the why and how of Trump 2.0
Chalk talk: Star power, top teams and No. 5 seeds headline the women's March Madness Sweet 16
Purdue returns to Sweet 16 with 76-62 win over McNeese in March Madness
(Reuters) - Catalent said on Friday it was unable to file its annual report with regulators on time as it requires additional time to complete "certain processes".
The contract drug manufacturer was expected to file the report on Aug. 29.
The company is awaiting the closing of the $16.5 billion takeover deal signed in February by Novo Holdings, the investment firm that has a controlling interest in Danish drugmaker Novo Nordisk.
Catalent expects the deal to close towards the end of the year.
Catalent is a contractor that does fill-finish work, which involves the filling and packaging of syringes and injection pens in sterile conditions, including Novo Nordisk's blockbuster drug Wegovy.
The U.S. Federal Trade Commission in May sought more information on the deal, after Novo Holdings prefiled an application seeking the antitrust agency's nod.
The company beat analysts' estimates for fourth-quarter revenue on Thursday, helped by its biologics segment that develops and manufactures cell and gene therapies.
(Reporting by Sriparna Roy in Bengaluru; Editing by Maju Samuel)
